Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
M651984-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$60.90
|
|
|
M651984-25mg
|
25mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$90.90
|
|
|
M651984-50mg
|
50mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$150.90
|
|
|
M651984-100mg
|
100mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$250.90
|
|
|
M651984-500mg
|
500mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$950.90
|
|
| Synonyms | AP32788 succinate | AP-32788 succinate | CS-0114257 | butanedioic acid;propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate | BCP33315 | MS-31177 | Propan-2-yl 2-[4-[2 |
|---|---|
| Specifications & Purity | ≥99% |
| Biochemical and Physiological Mechanisms | Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR . Mobocertinib succinat |
| Storage Temp | Store at 2-8°C,Desiccated |
| Shipped In |
Wet ice This product requires cold chain shipping. Ground and other economy services are not available. |
| Action Type | INHIBITOR |
| Mechanism of action | Epidermal growth factor receptor erbB1 inhibitor |
| Product Description |
Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR . Mobocertinib succinate can be used in NSCLC research In Vitro Mobocertinib succinate (1.5 nM-10 μM; 7 days) inhibits LU0387 (NPH) cells with IC 50 of 21 nM. Mobocertinib succinate (2 h) potently inhibits EGFR with common activating mutations (HCC827 (D), HCC4011 (L)) or with a T790M mutation (H1975 (LT)) more potently than WT EGFR (A431 (WT)). Mobocertinib succinate (0.1 nM-1 μM; 6 h) inhibits pEGFR and pERK1/2 in CUTO14 (ASV) cells. Mobocertinib succinate (0.3 nM-1 μM; 6 h) inhibits EGFR and downstream signaling. Mobocertinib succinate (0.01, 0.1 and 1 μM; 6 h) inhibits HER2 signaling in H1781 (HER2 Exon 20 G776>VC ), Ba/F3 (HER2 exon 20 YVMA ) cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: LU0387 (NPH) cells Concentration: 1.5 nM-10 μM Incubation Time: 7 days Result: Showed good inhibition activity for LU0387 (NPH) cells with IC 50 of 21 nM. Cell Viability AssayCell Line: A431 (WT), HCC827 (D), HCC4011 (L), H1975 (LT) cells Concentration: Incubation Time: 2 h Result: Inhibited EGFR with common activating mutations of HCC827 (D), HCC4011 (L) cells and T790M mutation of H1975 (LT) with IC 50 s of 4, 1.3 and 9.8 nM respectively, which more potently than WT EGFR (A431 (WT); IC 50 of 35 nM). Western Blot AnalysisCell Line: CUTO14 (ASV) cells Concentration: 0.1 nM-1 μM Incubation Time: 6 h Result: Robustly inhibited EGFR signaling, reaching 80% and 100% inhibition of phosphorylated EGFR (pEGFR) at concentrations of 100 nM and 1 μM, respectively. Western Blot AnalysisCell Line: HCC827 (D), HCC4011 (L), H1975 (LT) cells Concentration: 0.3 nM-1 μM Incubation Time: 6 h Result: Potently inhibited EGFR and downstream signaling in HCC827 (D), HCC4011 (L) and H1975 (LT) cells. Western Blot AnalysisCell Line: H1781 (HER2 Exon 20 G776>VC ), Ba/F3 (HER2 exon 20 YVMA ) cells Concentration: 0.01, 0.1 and 1 μM Incubation Time: 6 h Result: Inhibited HER2 signaling in H1781 and Ba/F3-HER2 exon 20 YVMA mutant cells at 0.1 μM with significantly decreased phosphorylations of HER2, AKT, and ERK1/2 in a dose-dependent manner. In Vivo Mobocertinib succinate (3, 10, 30 mg/kg; p.o.; once daily for 20 days) significantly induces tumor growth inhibition . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Athymic Nude-Foxn1 nu mice (human NSCLC H1975 LT tumor model) . Dosage: 3, 10, 30 mg/kg Administration: Oral; once daily for 20 days. Result: Decreased the mean tumor volume by 44% and 92% when at 3 mg/kg and 10 mg/kg, respectively, relative to the tumor size of vehicle group. Induced a 76% tumor regression relative to the pretreatment tumor size at 30 mg/kg. Form:Solid IC50& Target:EGFR exon 20 insertion HER2 EGFR (WT) |
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Benzenoids |
| Class | Benzene and substituted derivatives |
| Subclass | Anilides |
| Intermediate Tree Nodes | Not available |
| Direct Parent | 2'-Aminoanilides |
| Alternative Parents | N-alkylindoles Pyrimidinecarboxylic acids Methoxyanilines Indoles Aminophenyl ethers Phenoxy compounds N-arylamides Methoxybenzenes Dialkylarylamines Anisoles Aminopyrimidines and derivatives Alkyl aryl ethers N-methylpyrroles Fatty acids and conjugates Dicarboxylic acids and derivatives Heteroaromatic compounds Acrylic acids and derivatives Trialkylamines Secondary carboxylic acid amides Carboxylic acid esters Amino acids and derivatives Secondary amines Carboxylic acids Azacyclic compounds Organopnictogen compounds Organic oxides Hydrocarbon derivatives Carbonyl compounds |
| Molecular Framework | Not available |
| Substituents | 2'-aminoanilide - N-alkylindole - Aminophenyl ether - Methoxyaniline - Pyrimidine-5-carboxylic acid or derivatives - Pyrimidine-5-carboxylic acid - Indole or derivatives - Indole - Phenoxy compound - Methoxybenzene - Aniline or substituted anilines - Dialkylarylamine - N-arylamide - Tertiary aliphatic/aromatic amine - Phenol ether - Anisole - Aminopyrimidine - Alkyl aryl ether - Fatty acid - Substituted pyrrole - Pyrimidine - N-methylpyrrole - Dicarboxylic acid or derivatives - Acrylic acid or derivatives - Heteroaromatic compound - Pyrrole - Tertiary aliphatic amine - Tertiary amine - Secondary carboxylic acid amide - Carboxylic acid ester - Carboxamide group - Amino acid or derivatives - Azacycle - Organoheterocyclic compound - Secondary amine - Ether - Carboxylic acid - Carboxylic acid derivative - Organic nitrogen compound - Organic oxygen compound - Organopnictogen compound - Organic oxide - Hydrocarbon derivative - Organooxygen compound - Organonitrogen compound - Carbonyl group - Amine - Aromatic heteropolycyclic compound |
| Description | This compound belongs to the class of organic compounds known as 2'-aminoanilides. These are organic compounds containing an anilide moieties that carries an amino group at the 2-position of the benzene ring. |
| External Descriptors | Not available |
|
|
|
| IUPAC Name | butanedioic acid;propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate |
|---|---|
| INCHI | InChI=1S/C32H39N7O4.C4H6O4/c1-9-29(40)34-24-16-25(28(42-8)17-27(24)38(6)15-14-37(4)5)35-32-33-18-22(31(41)43-20(2)3)30(36-32)23-19-39(7)26-13-11-10-12-21(23)26;5-3(6)1-2-4(7)8/h9-13,16-20H,1,14-15H2,2-8H3,(H,34,40)(H,33,35,36);1-2H2,(H,5,6)(H,7,8) |
| InChIKey | YXYAEUMTJQGKHS-UHFFFAOYSA-N |
| Smiles | CC(C)OC(=O)C1=CN=C(N=C1C2=CN(C3=CC=CC=C32)C)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.C(CC(=O)O)C(=O)O |
| Isomeric SMILES | CC(C)OC(=O)C1=CN=C(N=C1C2=CN(C3=CC=CC=C32)C)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.C(CC(=O)O)C(=O)O |
| Alternate CAS | 2389149-74-8 |
| PubChem CID | 146026179 |
| Molecular Weight | 703.78 |
| Solubility | DMSO : 125 mg/mL (177.61 mM; Need ultrasonic) |
|---|---|
| Molecular Weight | 703.800 g/mol |
| XLogP3 | |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 16 |
| Exact Mass | 703.333 Da |
| Monoisotopic Mass | 703.333 Da |
| Topological Polar Surface Area | 188.000 Ų |
| Heavy Atom Count | 51 |
| Formal Charge | 0 |
| Complexity | 1030.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 2 |